Private Equity Archives - Page 5 of 5 - Gilde Healthcare

Menu
Menu
Home

latest news
Private Equity

GILDE HEALTHCARE COMPANY SYNEXA LIFE SCIENCES ACQUIRES ALDERLEY ANALYTICAL TO EXPAND BIOANALYSIS CAPABILITIES IN DRUG DEVELOPMENT

Synexa Life Sciences, a specialist biomarker and bioanalysis service provider, announces the acquisition of Alderley Analytical Ltd, based in Manchester, UK. The transaction marks an important milestone in Synexa’s ‘buy and build’ growth strategy, underpinning the company’s vision to be ‘the scientific partner of choice for biomarker and bioanalytical solutions’. Alderley Analytical’s CRO services complement Synexa Life Sciences’ established capabilities...
October 3, 2024

Gilde Healthcare portfolio company Eetgemak joins forces with TotaalVERS to become the leading integrated healthcare foodservice provider

test Combining TotaalVERS and Eetgemak will form a leading end-to-end foodservice provider*, offering a wide range of convenience meals, ingredients and groceries to the healthcare sector. The partnership emphasizes commitment to quality, service, and innovation in the healthcare market. Strengthening their joint position will further elevate service levels and product offerings of both companies. The combination […]

Gilde Healthcare sells RAD-x to a consortium of Swiss Life Asset Managers and Vesper Infrastructure Fund I

test Gilde Healthcare’s Private Equity Fund (“Gilde Healthcare”), a specialized healthcare investor, has reached a binding agreement to sell its majority stake in RAD-x to a consortium of Swiss Life Asset Managers and Vesper Next Generation Infrastructure Fund I. Gilde Healthcare invested in and, together with the founders, set-up RAD-x in 2016. Since its inception and […]

Gilde Healthcare company NIZO acquires lactic acid facility and strengthens partnership with DSM-firmenich

NIZO food research B.V. (“NIZO”) is proud to announce the signature of a long-term contract manufacturing partnership with dsm-firmenich. This strategic alliance encompasses the acquisition of the neighboring lactic acid facility from Vika Nutrition B.V., a Givaudan group company. With this move, NIZO widens its capabilities and...

Gilde Healthcare portfolio company Scharenborg Group appoints Johannes Schneider Littfeld as Chairman

The Scharenborg Group, a leading footcare technology firm has appointed Johannes Schneider Littfeld as Chairman to the Advisory Board. Johannes is an experienced executive in the MedTech- and patient care industry. He spent 15 years in senior management of Otto Bock, the global leader in Orthopedic Technology....

Swiss Dental Solutions AG partners with Gilde Healthcare to accelerate growth in the emerging ceramic dental implant markets

Swiss Dental Solutions AG (“SDS”) today announced that Gilde Healthcare’s Private Equity Fund (“Gilde Healthcare”), a specialized healthcare investor, has come to an agreement to acquire a majority of the shareholding of SDS through UNAC Holding AG as part of an international operational growth and development plan....

Gilde Healthcare invests in German precision surgical instruments contract manufacturer Koscher & Würtz

The acquisition of Koscher & Würtz represents a major step for Gilde Healthcare in forming a market leading instrument contract manufacturing group, following its initial investment in Chr. Diener, less than 18 months ago. Koscher & Würtz (K&W) will join as a group company next to Chr....

Gilde Healthcare company Noema Pharma raises CHF 103 million ($112 million)

Gilde Healthcare, a leading specialized healthcare investor, today announced that its portfolio company Noema Pharma, has raised an oversubscribed CHF 103 million ($112 million) Series B financing round from new and existing investors. Noema Pharma is a clinical-stage biopharma company targeting debilitating central nervous system (CNS) disorders....

Gilde Healthcare company Synexa Life Sciences celebrates its 20th anniversary

Two decades of advancing drug development programs through specialist biomarker and bioanalytical insights Synexa Life Sciences, a specialist biomarker and bioanalysis services provider, celebrates its 20th anniversary on March the 3rd 2023. Since its inception in 2003, Synexa Life Sciences has become a trusted partner to pharmaceutical,...
Loading...
These were all messages
04a2590a6e